Executive leadership and Board

Nuformix operations are managed by a leadership team and Board with extensive industry experience


Dr Alastair Riddell, Executive Chairman

Alastair has a wealth of leadership experience in public and private biotech companies, gained over 30 years in the pharmaceutical, life science and biotech industries, with 20 years as a Board Director.

After beginning his career as a medical doctor in hospital and general practice, he moved into clinical development for Lederle (now Pfizer) and Centocor (now J&J) and then sales and marketing for Amersham International (now GE Healthcare). This led to 12 years as CEO for three UK biotech companies, Pharmagene, Paradigm Therapeutics and Stem Cell Sciences, where he led significant fundraises including an IPO on the LSE main list and trade sales to Takeda in Japan and Stem Cells Inc. in the USA.

Alastair has also had several roles in UK government initiatives including assessing projects for Innovate UK funding. He then moved to Non-Executive roles including for NASDAQ-listed AzurRx (AZRX), Cristal Therapeutics and was Chairman of AIM quoted Feedback plc and Nemesis Biosciences.

Alastair has a BSc from Aston University, a MSc and MBChB from the University of Birmingham and an Honorary Degree of Doctor of Science from Aston University.

Dr Julian Gilbert, Non-Executive Director

Dr Julian Gilbert, Non-Executive Director, has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, British Technology Group plc (BTG) and Smith Kline & French (now GlaxoSmithKline plc).

Most recently, Julian was Co-founder and CEO of Acacia Pharma Group plc (Acacia), raising £100m in private and public funding and leading its flotation on Euronext in 2018. Prior to Acacia, he was co-founder and Commercial Director of Arakis Limited which was sold to Sosei in 2005 for £107 million. Julian has worked in business development since 1992 and has led multiple business development projects.

Julian has a degree in pharmacy and a PhD in pharmaceutics, both from the University of Nottingham.

Committees: Julian is Chairman of the Nomination Committee and a member of the Remuneration and Audit Committees.

Maddy Kennedy, Non-Executive Director

Maddy Kennedy, FCCA, specialises in growing life science businesses and has more than 20 years of experience in the sector, both in public and private companies.

Maddy runs a CFO portfolio through CFO4Growth and is currently Chief Financial Officer at Arquer Diagnostics and Tetris Pharma. Her previous contracts include being CFO for MyHealthChecked plc, Ieso Digital Health Ltd and PsiOxus Therapeutics Ltd. She was CFO for Lab21 Limited and Finance Director at Alliance Pharma plc, taking it through its IPO.

Committees: Maddy is Chairman of the Audit Committee and a member of the Nomination and Remuneration Committees.

Dr Joanne Holland, Consultant

Dr Joanne Holland is a consultant to Nuformix to advise, in particular, on solid form science and patenting.

Jo received a PhD in Chemistry from the University of Leeds sponsored by Pfizer. She joined the process R&D group at Millennium Pharmaceuticals before moving to a combined research and commercial role at Stylacats Limited. Following this Jo worked for Medeor Pharma Limited and Medeor Limited undertaking commercial and scientific research on new business and investment opportunities. Jo was a Co-founder of Nuformix.